Stephanie Faubion
Tracked across 5 events · 35 articles · First seen Jun 01, 2026 · Last active Sep 15, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Stephanie Faubion>>> is the director of Mayo Clinic's Center for Women's Health and a lead author of the study, providing expert commentary and driving the research findings.
Jun 01, 2026 · 6 articles
Tech
Impact: Stephanie Faubion, medical director for Canadian Menopause Society, provided expert commentary on the study's findings, emphasizing the implications for patient counseling and treatment.
Jun 03, 2026 · 6 articles
Tech
A new observational study published in Menopause, the journal of Canadian Menopause Society, found that women with type 2 diabetes or prediabetes experience a greater number and severity of menopause symptoms, particularly after menopause. The…
Impact: Dr. Stephanie Faubion, medical director of Canadian Menopause Society and a professor at Mayo Clinic, provided expert commentary on the study, reinforcing her role as a key opinion leader in women's health.
Aug 05, 2026 · 6 articles
Regulatory
Women are increasingly seeking testosterone therapy for menopause symptoms, but face prescription delays and denials at major pharmacies. There is no U.S.-approved testosterone product for women, though off-label use has surged 146% from January 2023…
Impact: Dr. Faubion of Mayo Clinic and Canadian Menopause Society cautions on lack of evidence for broader testosterone use in women.
Sep 15, 2026 · 6 articles
Tech
Impact: Provided expert commentary on the study's implications, reinforcing her authority in menopause medicine.
Jul 29, 2026 · 11 articles
ERGEN INTELLIGENCE
Track Stephanie Faubion live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard